Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Lifeloc Technologies (LCTC) Asset Writedowns and Impairment (2016 - 2024)

Lifeloc Technologies has reported Asset Writedowns and Impairment over the past 9 years, most recently at $1000.0 for Q4 2024.

  • Quarterly results put Asset Writedowns and Impairment at $1000.0 for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $5175.0 (changed N/A YoY), and the annual figure for FY2025 was $1500.0, down 25.0%.
  • Asset Writedowns and Impairment for Q4 2024 was $1000.0 at Lifeloc Technologies, down from $4175.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for LCTC hit a ceiling of $20101.0 in Q4 2020 and a floor of -$49000.0 in Q2 2021.
  • Median Asset Writedowns and Impairment over the past 3 years was $2000.0 (2020), compared with a mean of -$2832.1.
  • Biggest five-year swings in Asset Writedowns and Impairment: skyrocketed 368.01% in 2020 and later tumbled 1733.33% in 2021.
  • Lifeloc Technologies' Asset Writedowns and Impairment stood at $20101.0 in 2020, then tumbled by 343.77% to -$49000.0 in 2021, then soared by 102.04% to $1000.0 in 2024.
  • The last three reported values for Asset Writedowns and Impairment were $1000.0 (Q4 2024), $4175.0 (Q3 2024), and -$49000.0 (Q2 2021) per Business Quant data.